Este sitio web utiliza tecnologías de seguimiento, como cookies, para brindar una mejor experiencia al usuario. Si continúa utilizando este sitio, entonces reconoce nuestro uso de tecnologías de seguimiento. Para obtener información adicional, consulte nuestra Política de Privacidad.
While current treatment and liver transplantation strategies are reasonably effective for patients with early stage liver cancer, once the disease has advanced it becomes much harder to treat. Checkpoint immunotherapy has provided relief for some patients with advanced liver cancer, but the majority of patients still either don’t respond to the treatment or else develop resistance after initially responding. To address this, Dr. Guangchuan Wang is using a novel gene-editing approach to discover new factors that are responsible for resistance to immunotherapy. Identifying and validating the contribution of these factors will provide insights that could be used to improve immunotherapy approaches for liver cancer by helping doctors determine treatments might work best for which patients as well as highlighting novel targets for which future therapies could be developed.
Yale University | Liver Cancer | 2017 | Sidi Chen, Ph.D.
*Los resultados de la inmunoterapia pueden variar de un paciente a otro.
Comuníquese con nosotros
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Directorio de Personal
This September for Childhood Cancer Awareness Month, we look at new research, new treatments, and how we are working toward a future immune to childhood cancer.
This September for Gynecologic Cancer Awareness Month, we reflect on new treatments, research discoveries, and how CRI is making its impact on a future immune to cervical, ovarian, and uterine cancers.